Editas Medicine, INC. (EDIT) — SEC Filings

Overview

Editas Medicine, INC. (EDIT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Editas Medicine, Inc. (EDIT) reported a net loss of $25.1 million for the three months ended September 30, 2025, a significant improvement from the $62.1 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $154.4 million, down from $191.7 milli

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 1 bullish, 34 neutral, 1 mixed. The dominant filing sentiment for Editas Medicine, INC. is neutral.

Filing Type Overview

Editas Medicine, INC. (EDIT) has filed 19 8-K, 4 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• 8-K Filing — 8-K · Mar 27, 2026
• Editas Narrows Losses, Boosts Revenue Amid Restructuring — 10-Q · Nov 10, 2025 Risk: high
  Editas Medicine, Inc. (EDIT) reported a net loss of $25.1 million for the three months ended September 30, 2025, a significant improvement from the $62.1 millio
• Editas Medicine Files 8-K Report — 8-K · Oct 9, 2025 Risk: low
  On October 9, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Sta
• Editas Medicine Files 8-K — 8-K · Sep 2, 2025 Risk: low
  Editas Medicine, Inc. filed an 8-K on September 2, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, othe
• Editas Medicine's Restricted Cash Holds Steady at $3,877 — 10-Q · Aug 12, 2025 Risk: medium
  Editas Medicine, Inc. reported restricted cash of $3,877 as of June 30, 2025, which remained unchanged from June 30, 2024. The filing indicates no significant c
• Editas Medicine Files 8-K Report — 8-K · Jun 12, 2025 Risk: low
  On June 12, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and
• Editas Medicine Files 8-K with Corporate Updates — 8-K · Jun 2, 2025 Risk: medium
  Editas Medicine, Inc. filed an 8-K on May 29, 2025, reporting on several key events. These include the departure of directors or certain officers, the election
• Editas Medicine Files 8-K Report — 8-K · May 14, 2025 Risk: low
  On May 14, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regul
• Editas Medicine Files 8-K Report — 8-K · May 13, 2025 Risk: low
  On May 13, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events
• Editas Medicine Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  Editas Medicine, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Cambridge, MA, is involved in biological products.
• Editas Medicine 2025 Proxy Statement: Executive Pay Details — DEF 14A · Apr 15, 2025 Risk: medium
  Editas Medicine, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes in
• Editas Medicine Appoints New CFO and Directors — 8-K · Mar 20, 2025 Risk: medium
  Editas Medicine, Inc. announced on March 18, 2025, changes in its board and executive team. The company elected two new directors, Dr. Andrew G. Webb and Ms. Sa
• 10-K Filing — 10-K · Mar 5, 2025
• Editas Medicine Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Editas Medicine, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information rel
• Editas Medicine Announces Executive & Board Changes — 8-K · Dec 17, 2024 Risk: medium
  Editas Medicine, Inc. announced on December 16, 2024, a series of executive and board changes. These include the appointment of Dr. Michael A. Caligiuri as Chie
• Bristol Myers Squibb to Acquire Editas Medicine for $1.5 Billion — 8-K · Dec 12, 2024 Risk: medium
  Editas Medicine, Inc. announced on December 11, 2024, that it has entered into a definitive agreement to be acquired by Bristol Myers Squibb Company for $4.00 p
• Editas Medicine Files 8-K with Corporate Updates — 8-K · Dec 10, 2024 Risk: low
  Editas Medicine, Inc. filed an 8-K on December 10, 2024, reporting events as of December 6, 2024. The filing includes amendments to its articles of incorporatio
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Editas Medicine Files 8-K for Financials — 8-K · Nov 4, 2024 Risk: low
  Editas Medicine, Inc. filed an 8-K on November 4, 2024, to report on its results of operations and financial condition, as well as to file financial statements
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Editas Medicine Files 8-K on Operations and Financials — 8-K · Oct 22, 2024 Risk: low
  On October 22, 2024, Editas Medicine, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also included Regulation FD d
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• Editas Medicine Files 8-K with Material Agreement — 8-K · Oct 4, 2024 Risk: medium
  On October 3, 2024, Editas Medicine, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also issued a Regula
• Editas Medicine Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
  Editas Medicine, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company's financia
• SC 13G/A Filing — SC 13G/A · Jul 10, 2024
• Editas Medicine Announces Executive and Board Changes — 8-K · Jun 27, 2024 Risk: medium
  Editas Medicine, Inc. announced on June 27, 2024, the departure of its Chief Medical Officer, Dr. Michael Cheng. The company also appointed Dr. Sarah Boyce as t
• Editas Medicine Files 8-K Report — 8-K · Jun 14, 2024 Risk: low
  On June 14, 2024, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
• Editas Medicine Files 8-K on Shareholder Vote Matters — 8-K · May 31, 2024 Risk: low
  Editas Medicine, Inc. filed an 8-K on May 30, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the specific ma
• Editas Medicine Files 8-K on Financials — 8-K · May 8, 2024 Risk: low
  Editas Medicine, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits.
• Editas Medicine Files DEF 14A for Annual Meeting and Executive Compensation — DEF 14A · Apr 16, 2024 Risk: medium
  Editas Medicine, Inc. (EDIT) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. Editas Medicine, Inc. filed a DEF 14A form on April 16, 2024. The
• SC 13G/A Filing — SC 13G/A · Apr 10, 2024
• Editas Medicine Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  Editas Medicine, Inc. (EDIT) filed a Annual Report (10-K) with the SEC on February 28, 2024. Editas Medicine, Inc. filed its 2023 Form 10-K on February 28, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Amends Editas Medicine Stake, Maintains Passive Position — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership in Editas Medicine, Inc. as of December 31, 2023. This filing, Amendment
• State Street Corp. Maintains Passive Stake in Editas Medicine — SC 13G/A · Jan 10, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 10, 2024, disclosing its ownership in Editas Medicine, Inc. as of

Related Companies

BMY · VRTX · CRSP · NTLA · EDAS

Frequently Asked Questions